Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Transmucosal Drug Delivery Devices Market Size And Revenue Outlook Through 2030
The transmucosal drug delivery devices market size has experienced robust growth in recent years. This market is projected to expand from $54.63 billion in 2025 to $59.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. Historically, this growth can be attributed to several factors, including the expansion of non-invasive drug delivery approaches, a rising demand for pain management therapies, increased use of hormone replacement treatments, growth in pharmaceutical formulation innovation, and wider acceptance of transmucosal therapies.
The transmucosal drug delivery devices market is anticipated to show significant expansion over the coming years, with its value projected to reach $81.52 billion in 2030, growing at a compound annual growth rate (CAGR) of 8.1%. This upward trend during the forecast period can be linked to several factors, including the increasing progress in personalized medicine solutions, heightened investments in advanced drug delivery platforms, a rising need for at-home drug administration devices, the broadening application of biologics and peptide-based drugs, and an increase in regulatory approvals for innovative delivery systems. Noteworthy trends for this period encompass the growing adoption of buccal and sublingual delivery methods, an escalating demand for drug administration with rapid onset, the spread of microneedle and active delivery technologies, an enhanced focus on patient-convenient drug delivery devices, and a stronger emphasis on dose precision and bioavailability.
Get A Free Sample Report With In-Depth Market Insights:
Transmucosal Drug Delivery Devices Market Demand Drivers Opening New Revenue Streams
The increasing incidence of chronic illnesses is anticipated to boost the expansion of the transmucosal drug delivery devices market in the foreseeable future. A chronic illness is defined as a persistent ailment that usually advances gradually and endures for an extended period, frequently necessitating continuous medical intervention to manage its manifestations and avert adverse effects. The rise in chronic conditions can be attributed to several factors, including lifestyle choices, an aging global demographic, environmental influences, difficulties within healthcare systems, and increasing urbanization. For chronic ailments, transmucosal drug delivery devices serve to ensure regulated and effective administration of medicines, thereby maintaining consistent therapeutic concentrations crucial for symptom control and enhancing patient compliance. As an illustration, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) had a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar levels, insufficient for a diabetes classification) in 2023. This represented an 18% increase from 3,065,825 cases reported in 2022. Consequently, the expanding occurrence of chronic diseases is fueling the transmucosal drug delivery devices market.
Transmucosal Drug Delivery Devices Market Segment Analysis Spotlighting Growth Areas
The transmucosal drug delivery devices market covered in this report is segmented –
1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals
Subsegments:
1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films
2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays
3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators
4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels
5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels
Transmucosal Drug Delivery Devices Market Trends Powering Strategic Industry Growth
Leading companies in the transmucosal drug delivery sector are developing advanced smart platforms, including proprietary transdermal patch delivery systems that boost drug absorption and enhance patient compliance and convenience. These proprietary transdermal patch delivery platforms refer to specialized, company-owned technologies for administering medications through the skin, ensuring controlled release and improved therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, introduced STARSILON, a new proprietary transdermal patch delivery platform, designed for longer-duration therapeutic delivery of difficult-to-formulate active pharmaceutical ingredients (APIs). This expands transdermal drug delivery options for challenging APIs, enhancing therapeutic efficacy with sustained delivery rates.
Transmucosal Drug Delivery Devices Market Top Companies Driving Competitive Growth
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd
View The Full Transmucosal Drug Delivery Devices Market Report:
Transmucosal Drug Delivery Devices Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









